CYP51/HDAC-IN-1 is a potent, orally activeCYP51/HDACdual inhibitor. CYP51/HDAC-IN-1 inhibits important virulence factors and down-regulated resistance-associated genes. CYP51/HDAC-IN-1 exhibits potent therapeutic effects for both tropical candidiasis and cryptococcal meningitis^[1].

CYP51/HDAC-IN-1 (compound A5) exhibits the best inhibitory activity against bothCandida tropicalis (C. tropicalis)andCryptococcus neoformans (C. neoformans)with an MIC₈₀of 0.5 μg/mL^[1].
CYP51/HDAC-IN-1 (human umbilical vein endothelial cell line (HUVEC)) shows low toxicity to human normal cells (IC₅₀= 5.9 μg/mL (10.36 μM))^[1].
CYP51/HDAC-IN-1 inhibits biofilm formation ofC. tropicalisandC. neoformansin a dose-dependent manner^[1].
CYP51/HDAC-IN-1 reduces the virulence ofC. neoformansthrough down-regulating capsule-associated genes CAP10 and CAP60^[1].
CYP51/HDAC-IN-1 increases the activity against FLC-resistantC. tropicalisby inhibits the overexpression of efflux pump genes, and down-regulated ERG11 gene in ergosterol biosynthetic pathway^[1].
CYP51/HDAC-IN-1 exhibits HDAC inhibitory activity (IC₅₀=2.38 μM) and down-regulated HDAC genes (Rpd3, Hos1, Hos2, Clr61, Clr62, Hda1 and Hos3)^[1].

CYP51/HDAC-IN-1 (20 mg/kg; p.o.; once a day for 5 consecutive days) exhibits potent therapeutic effects for both tropical candidiasis and cryptococcal meningitis (CM)^[1].

586.67

C₃₀H₄₀F₂N₆O₄

2502095-64-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.